W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies

X

Opinion of the Transparency Council

04 July, 2024

Opinion of the Transparency Council – diazepamum

27 June, 2024

Opinion of the Transparency Council – propranolol

27 June, 2024

Opinion of the Transparency Council – atorvastatinum, lovastatinum, simvastatinum

27 June, 2024

Opinion of the Transparency Council – Breast cancer prevention program for women residing in the Municipality of Tczew for the years 2024-2025

27 June, 2024

Opinion of the Transparency Council – Program of early detection of breast cancer among female residents of Olesnica for the year 2024

20 June, 2024

Opinion of the Transparency Council – prednisonum

20 June, 2024

Opinion of the Transparency Council – salbutamolum

20 June, 2024

Opinion of the Transparency Council – amantadine

15 September, 2022

Opinion of the Transparency Council – sirolimus

16 August, 2022

Opinion of the Transparency Council – health policy programme on infertility treatment (Rzeszów)

16 August, 2022

Opinion of the Transparency Council – health policy programme on breast cancer (Municipality of Toszek)

16 August, 2022

Opinion of the Transparency Council – changes to the drug programme B.82

16 August, 2022

Opinion of the Transparency Council – active substance etanercept

16 August, 2022

Opinion of the Transparency Council – changes to the drug programme B.44

27 June, 2022

Opinion of the Transparency Council – health policy programme of the Municipality of Zgierz in the scope of prevention and correction of vision in children

27 June, 2022

Opinion of the Transparency Council – amendments to PL B.59 on melanoma of the skin or mucous membranes

27 June, 2022

Opinion of the Transparency Council – health policy programme of Piaseczno Poviat in the scope of prostate cancer prevention

23 June, 2022

Opinion of the Transparency Council – health policy programme for the residents of the Warmińsko-Mazurskie Voivodeship within the scope of support for diagnostics and treatment of infertility excluding the methods of medically assisted reproduction

18 May, 2022

Opinion of the Transparency Council – carbamazepine

Home page

News Publications Publikacje BIP

#webinar agenda Aktualności announcement of the President azathioprinum Bimzelx Collegium AOTMiT colorectal cancer communication Communication from the Transparency Council Communication on the Tariff Council Cost Accounting Standard Council for Tariffs Affairs covering neonatal care cyclophosphamidum Data acquisition dental treatment services diseases of the organ of vision drug programme Empliciti entecavirum etanercept Fycompa gastroscopy glaucoma health policy program health policy programme health policy programme on breast cancer health policy programme on infertility treatment Health Policy Programmes Impavido in vitro Inovelon Jardiance Meeting of the Transparency Council methotrexatum Milupa Basic-P minimum wage increases mycophenolate mofetil new new tariffs news Notice Notice of the President Ontozry Onureg Opdivo Opdivo (nivolumab)opinion Opinion of the President Opinion of the Transparency Council Ospolot Ozurdex perinatal care Ponvory Position of the Transparency Council Press conference Recommendation Recommendation of the President Renastep report Rezurock sirolimus Suliqua Tariff Council Tariffs Council Tarification Plan 2025 tenofovirum disoproxilum the drug programme B.44 the drug programme B.82 The Meeting of the Tariffs Council trainings Transparency Council Tremfya update Vivitrol Yervoy

Pokaż więcej ↓

Pokaż mniej ↑